240 results about "Post immunization" patented technology

A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.

The invention discloses a method of preparing a bombyx mori silk fibroin specific antibody by utilizing a characteristic polypeptide. The method comprises the following steps: synthesizing a "CGAGAGSGAGAGS" polypeptide sequence by utilizing an Fmoc method, coupling the polypeptide with keyhole limpet hemocyanin (KLH) through the cysteine on the N terminus of the polypeptide so as to obtain a complete antigen; diluting the complete antigen with normal saline, mixing the diluted complete antigen with a complete Freund's adjuvant, adding streptomycin and penicillin to carry out an emulsion treatment so as to obtain a primary immunized antigen emulsion, subjecting a rabbit to a primary immunization by using the primary immunized antigen emulsion, then subjecting the rabbit to a strengthened immunization, wherein the strengthened immunization uses a strengthened immunized antigen emulsion, which is prepared by the following steps: mixing the diluted complete antigen with an incomplete Freund's adjuvant, and then adding streptomycin and penicillin to carry out an emulsion treatment so as to obtain the target product; collecting the blood of the immunized rabbit, when the antibody titer in the rabbit blood sample reaches 1/10000; making the blood blocks fully contract to completely separate out the antiserum, then collecting the antiserum, and subjecting the antiserum to a centrifugation treatment so as to obtain a supernate.

The present invention comprises the use of follicular dendritic cells (FDCs) or FDC-like cells to generate FDC-dependent, but T cell-independent, B cell responses to T cell-dependent antigens, with antigen-specific and polyclonal antibody production in ˜48 h. In another embodiment, a germinal center (GC) lymphoid tissue equivalent (LTE) was used to generate antigen-specific IgM, followed by switching to IgG. The GC LTE model can be used in vaccine assessment. Dual forms of immunogen were used in the GC LTE and in vivo. Dual immunogens resulted in rapid, specific IgM responses and enhanced IgG responses. This vaccine design approach can be used, for example, to provide rapid IgM protection (˜24-48 h) and high-affinity IgG more quickly in people moving to areas with endemic disease, or in people with T cell insufficiencies, who can be immunized to rapidly generate protective IgM.

The invention provides an immunity enhancing agent, an inactivated vaccine, and a preparation method thereof. The invention relates to the field of biopharmaceutical. The immunity enhancing agent comprises 0.1-21mg/mL of monophosphoryl lipid A, 1.5-125mg/mL of muramyl dipeptide, and 0.7-4.5mg/mL of beta-glucan. The invention also provides the inactivated vaccine comprising the immunity enhancing agent, and a preparation method of the inactivated vaccine. According to the invention, the immunity enhancing agent is mixed with an inactivated antigen solution, such that a water-phase solution is obtained; and the water-phase solution is mixed with an oil-phase solution, such that the inactivated vaccine is obtained. According to the immunity enhancing agent provided by the invention, with a synergetic effect of the components, body immunity level can be improved, and immune response to antigen can be improved, such that antibody level after immunization can be increased, immune window period can be shortened, and vaccine immunization effect can be enhanced. According to the inactivated vaccine comprising the immunity enhancing agent, antibody level after immunization is high, a protection period is long, and immunization window period is short.

The invention discloses a rabbit triple inactivated vaccine, a preparation method and the application thereof; the rabbit triple inactivated vaccine is formed mainly by rabbit hemorrhagic disease virus liquid which is inactivated and detoxified, rabbit pasteurella multocida liquid and rapid A type clostridium perfringens liquid which have 1:1:2 volume ratio; in the invention, by optimizing culture technology, concentration technology and immunizing dose and other measures, the rabbit triple inactivated vaccine which has good immunity effect and safety is obtained and can effectively control the rabbit hemorrhagic disease, the pasteurella multocida disease and the pasteurella multocida disease (A type) and reduce vaccine injection times of farmers, so as to reduce the stress reaction of animals and improve the production performance. The clinical application proves that the immunization effect of the rabbit triple inactivated vaccine is ideal, each rabbit is vaccinated with 2ml and has immunity after 5-7 days, the immune period is at least 180 days, and the immune safety is good without toxic and side effect.

The invention discloses a method for refining chicken egg yolk antibodies against Escherichia coli, which comprises the following steps of: culturing by adopting formaldehyde, thiomersalate and a white oil adjuvant to prepare antigen solution; immunizing healthy chickens by using the antigen solution, and collecting immune eggs; extracting egg yolk antibodies from the immune eggs; and purifying by adopting ammonium sulfate to obtain the chicken egg yolk antibodies against the Escherichia coli. For the chicken egg yolk antibodies against the Escherichia coli, pili are collected first, and then Escherichia coli antibodies in the chicken egg yolk are collected after organism immunization of chickens, wherein when the Escherichia coli antibodies in the chicken egg yolk are collected, ammonium sulfate solution is adopted for purification. Experiments prove that the potency of the chicken egg yolk antibodies against the Escherichia coli is obviously improved.

Genes encoding herpes simplex virus type 2 (HSV-2) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. In a DNA titration, it was found that a single immunization of ≧0.5 μg of (one) PNV, gave >90% seroconversion by ten weeks post immunization. Immune antisera neutralized both HSV-2 and HSV-1 in cell culture. When animals were challenged with HSV-2, significant (p<0.001) protection from lethal infection was achieved following PNV vaccination. DNA constructs may be full-length, truncated and/or mutated forms and may be delivered along or in combination in order to optimize immunization and protection from HSV infection.

The invention discloses a novel coronavirus vaccine based on chimeric virus-like particles, and the vaccine contains chimeric virus-like particles as effective ingredients. The chimeric virus-like particles are mainly formed by the aggregation of a type of recombinant chimeric proteins, and the recombinant chimeric proteins are obtained by fusing the S protein receptor binding region of SARS-CoV-2virus into the major immune determining region of HBcAg. The vaccine of the present invention can produce a strong immune response in human bodies, and humans can resist new coronavirus infections after immunization.

The invention relates to an imidacloprid pesticide against monoclonal antibody and a preparation method thereof, and belongs to the technical field of biology. The preparation method comprises the following steps of: immunizing a BALB/c mouse by using a coupling substance of immune hapten 1-[6-(2-carboxyethylsulfenyl-3-pyridine) methyl]-N-nitro-2-imidazoline imine and bovine serum albumin, preparing hybrid tumor cells from spleen cells and myeloma cells Sp2/0 of the immunized mouse by the hybrid tumor technology, and obtaining hybrid tumor strains 2F11/A9 capable of stably secreting the imidacloprid pesticide against monoclonal antibody. By effectiveness verification, the antibody can be used for sensitive and quick detection of imidacloprid residues in agricultural production environments and agricultural products. The preparation technique for the imidacloprid pesticide against monoclonal antibody is simple and feasible, does not need special instruments and equipment in the whole preparation process of the antibody, and is easy for scale production in factories.

The invention provides novel coronavirus SARS-CoV-2mRNA vaccines and a preparation method and application thereof. The invention provides three mRNA vaccines, namely RBD, S1 and S vaccines. The RBD vaccine disclosed by the invention can induce a high-titer antigen-specific IgG antibody and a virus neutralization antibody after immunization with one dose, the high-titer neutralization antibody can be maintained for at least 26 weeks, and remarkable immune protection can be provided for human ACE2 transgenic mice in serum adoptive transfer protection experiments. The RBD and S vaccine disclosed by the invention can induce immune protection capable of completely resisting SARS-CoV-2 virus infection in the human ACE2 transgenic mice after immunization with two doses. A large number of experimental results show that the mRNA vaccine provided by the invention has good immunogenicity, forms powerful immune protection after immunizing an organism, and has a huge development potential.

The invention provides a p porcine pseudorabies virus and vaccine composition and applications thereof, belonging to the field of biotechnology. The microbial preservation number of the porcine pseudorabies virus PRV-JS strain is CGMCCNO.6604. The invention further provides a vaccine composition which comprises an inactivated porcine pseudorabies virus PRV-JS strain and adjuvant acceptable on veteriary pharmacy. The vaccine composition further comprises a carrier acceptable on the veterinary pharmacy. The porcine pseudorabies virus PRV-JS strain is screened from porcine pseudorabies prevalent strains separated from all pig farms and has good immunogenicity, and can be used as inactivated vaccine production virus seeds or virus seeds for testing. After being immunized by the vaccine composition, pigs have higher produced antibody level and the lasting period is long. The vaccine composition prepared by adopting the porcine pseudorabies virus PRV-JS strain can be used for preventing the sow abortionbreeding difficulty and mortality syndromeboar infertility caused by the porcine pseudorabies virus, boar infertility and pseudorabies of other pigs.

The present invention relates to a streptococcus antigen C5a and a preparation method thereof. The streptococcus protective antigen C5a is an SEZC5a recombinant protein, which consists of 571 amino acids and has a molecular weight of 60.3kDa; a forward primer has one BamHI restriction enzyme cutting site, and a reverse primer has one EcoRI restriction enzyme cutting site. According to the preparation method of the streptococcus protective antigen C5a, the SEZ C5a recombinant protein is treated with cloning, expression and purification; and a series of biological engineering technologies and experiments on mice are applied to conduct system analysis on an rSCPZ. After vaccination, the rSCPZ can provide high protective efficacy; an anti-rSCPZ mice double-immunized serum has significant passive immune protection on mice; and the mice immunized by the rSCPZ show high level of antibody titer in serum. The anti-rSCPZ antibody can induce high level of bactericidal capability; an scpZ gene has a transcription level in SEZ (Streptococcus zooepidemicus) infected mice higher than that of culture in vitro; and the rSCPZ can adhere to hep-2 cells and inhibit cell infection ability of SEZ.

The invention discloses an attenuated Salmonella pullorum and application thereof. By using gene knockout technology, the in vivo colonization gene and the main virulence gene of Salmonella pullorum are deleted, thus obtaining an dual-gene-deleted attenuated Salmonella pullorum SM091-DED strain; and the microbiological preservation number of the strain is CGMCC NO.4604. The virulence of the attenuated Salmonella pullorum disclosed by the invention is obviously reduced, and the in vivo colonization time is short after the attenuated Salmonella pullorum is inoculated into a host; the herd infection test shows that the attenuated Salmonella pullorum has no horizontal transmission capability; the attenuated Salmonella pullorum provides full cross protection for homotype and allotype high-virulence Salmonella pullorum; and after SPF (Specific Pathogen Free) chicks are immunized, the infection of the high-virulence strain can be effectively eliminated, and the herd infection can not be caused. Thus, the invention provides a safe, fine-immunogenicity and low-virulence Salmonellosis avium attenuated live vaccine for preventing Salmonellosis avium.

The invention provides preparation methods for duck hepatitis virus immunogen and hyperimmune serum and application of the duck hepatitis virus hyperimmune serum. According to the preparation methods and the application of the duck hepatitis virus hyperimmune serum, the duck hepatitis virus immunogen is obtained through inoculating a serum 1 type duck hepatitis virus CH60 strain DHAV-1 (Duck Hepatitis A Virus type 1) or a serum 3 type duck hepatitis virus CH1 strain DHAV-3 (Duck Hepatitis A Virus type 3) to an allantoic cavity of a chick embryo of 9-10 days old or a duck embryo of 10-12 days old and carrying out proliferation and treatment, and the hyperimmune serum is obtained through mixing the duck hepatitis virus immunogen with a Freund's complete adjuvant or Freund's incomplete adjuvant to prepare solutions of different concentrations, carrying out repeated immunization on immune animals and then sampling and collecting blood and can be applied to the diagnosis and detection on a duck hepatitis virus. The preparation methods provided by the invention have the advantages that the conditional requirements are low, the operation is simple, and the obtained immunogen can meet the requirements on the preparation of specific antiserum.

The invention provides an aspergillus fumigatus galactomannan antigen resisting polyclonal antibody and a preparation method thereof. The preparation method of the polyclonal antibody includes: adopting aspergillus fumigatus galactomannan prepared by affinity chromatography to perform animal immunization, taking blood from immunized animals to obtain serum, and purifying the serum by a saturated ammonium sulfate salting-out method and immunoaffinity chromatography to obtain the polyclonal antibody. The polyclonal antibody prepared according to the method is high in titer and purity, is the first aspergillus fumigatus galactomannan antigen resisting polyclonal antibody prepared by immunoaffinity chromatography in China and has a promising application prospect in the field of medical and scientific research.

The invention relates to the field of viruses, in particular to a porcine pseudorabies double gene deletion mutant virus strain and an establishment method thereof. The virus strain is a gE, gI double gene deletion strain, the preservation number is CCTCC NO. V201749, preservation unit is: China's typical culture collection center, the preservation address is: Wuhan University, Wuhan, China, the postcode is 430072. rPRV HN2012-gE-/gI-immunized piglets established do not have any adverse reactions during the experiment, the neutralizing antibody level verifies that the deletion virus maintains good immunogenicity, the obtained rPRV HN2012-gE-/gI-double gene deletion virus is safe for the piglets, PRV (pseudorabies virus) specific antibody can be produced effectively and rapidly after immunization, and the porcine pseudorabies double gene deletion mutant virus strain is a vaccine strain which is expected to be used in the prevention and control of PRV epidemic.